News
Boston Scientific Q2 Earnings Call Highlights
Key Points
- Interested in Boston Scientific Corporation? Here are five stocks we like better.
- Strong Q2 results, lower outlook: Boston Scientific posted 7% organic revenue growth and adjusted EPS
AxoGen Q2 Earnings Call Highlights
Key Points
- Interested in AxoGen, Inc.? Here are five stocks we like better.
- Strong revenue growth: AxoGen’s second-quarter revenue rose 23.1% year over year to $69.7 million, driven largely by
Anika Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Anika Therapeutics Inc.? Here are five stocks we like better.
- Second-quarter performance strengthened: Revenue rose 16% year over year to $32.6 million, while gross
Meridian Q2 Earnings Call Highlights
Key Points
- Interested in Meridian Holdings Inc.? Here are five stocks we like better.
- Meridian delivered stronger financial results: Second-quarter revenue rose 16% year over year to $50.2
EQS-News: Dr. Sven K. Weber tritt Nachfolge von Adriaan Moelker als Vorstandsvorsitzender der BRAIN Biotech AG an
EQS-News: Dr. Sven K. Weber tritt Nachfolge von Adriaan Moelker als Vorstandsvorsitzender der BRAIN Biotech AG an
EQS-Adhoc: BRAIN Biotech AG bestellt Dr. Sven K. Weber zum 01. Oktober 2026 als neuen Vorsitzenden des Vorstands
EQS-Adhoc: BRAIN Biotech AG bestellt Dr. Sven K. Weber zum 01. Oktober 2026 als neuen Vorsitzenden des Vorstands
Intellia Therapeutics Aktie: lonvo-z vor Zulassungsantrag 2026
Intellia Therapeutics nähert sich einem kritischen Wendepunkt. Bei einem aktuellen Kurs von 9,57 Euro…
Der Beitrag Intellia Therapeutics Aktie: lonvo-z vor Zulassungsantrag 2026 erschien zuerst auf
Rithm Property Trust Q2 Earnings Call Highlights
Key Points
- Interested in Rithm Property Trust Inc.? Here are five stocks we like better.
- Rithm Property Trust reported essentially flat second-quarter earnings, with book value per share
Rithm Capital Q2 Earnings Call Highlights
Key Points
- Interested in Rithm Capital Corp.? Here are five stocks we like better.
- Rithm Capital reported strong second-quarter distributable earnings of $338.9 million, or $0.60 per diluted
Repligen Q2 Earnings Call Highlights
Key Points
- Interested in Repligen Corporation? Here are five stocks we like better.
- Strong second-quarter performance: Repligen reported $204 million in revenue, up 12% year over year and 13%
5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys?
Key Points
- Interested in Rocket Lab Corporation? Here are five stocks we like better.
- Space stocks have fallen 50% to more than 70% from their highs after SpaceX's Nasdaq debut triggered a
Champions Oncology Q4 Earnings Call Highlights
Key Points
- Interested in Champions Oncology, Inc.? Here are five stocks we like better.
- Record fiscal 2026 performance: Revenue reached $59.4 million, up from the prior year, and adjusted
MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE
Key Points
- Interested in MannKind Corporation? Here are five stocks we like better.
- MannKind received FDA approval for Furoscix ReadyFlow, an auto-injector that delivers an 80 mg dose of
West Pharmaceutical Services Q2 Earnings Call Highlights
Key Points
- Interested in West Pharmaceutical Services, Inc.? Here are five stocks we like better.
- West Pharmaceutical Services beat second-quarter expectations, with revenue up 13% organically
AtriCure Q2 Earnings Call Highlights
Key Points
- Interested in AtriCure, Inc.? Here are five stocks we like better.
- AtriCure posted strong Q2 2026 results, with revenue up 12.8% to $153.6 million and a return to GAAP
FirstService Q2 Earnings Call Highlights
Key Points
- Interested in FirstService Corporation? Here are five stocks we like better.
- FirstService posted modest Q2 growth, with revenue up 2% year over year to $1.45 billion, adjusted
Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment
Key Points
- Interested in Ocular Therapeutix, Inc.? Here are five stocks we like better.
- Ocular Therapeutix says it remains on track to file an NDA for AXPAXLI in wet age-related macular
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach
Key Points
- Interested in Repligen Corporation? Here are five stocks we like better.
- Repligen is acquiring BioLife Solutions in a deal valued at about $1.5 billion, paying $31 per share in a
Chubb Q2 Earnings Call Highlights
Key Points
- Interested in Chubb Limited? Here are five stocks we like better.
- Chubb delivered a strong Q2 with core operating earnings of $2.8 billion, or $7.26 per share, up sharply from a
Healthcare Services Group Q2 Earnings Call Highlights
Key Points
- Interested in Healthcare Services Group, Inc.? Here are five stocks we like better.
- Healthcare Services Group reported Q2 2026 revenue of $470.8 million and net income of $22.7
EQS-News: BaFin-Prüfung betrifft Bilanzierung der Pentixapharm-Abspaltung im Konzernabschluss 2024 – möglicher Gewinn aus aufgegebenem Geschäftsbereich ohne Auswirkung auf operative Kennzahlen
EQS-News: BaFin-Prüfung betrifft Bilanzierung der Pentixapharm-Abspaltung im Konzernabschluss 2024 – möglicher Gewinn aus aufgegebenem Geschäftsbereich ohne Auswirkung auf operative Kennzahlen
Paladin Energy Q4 Earnings Call Highlights
Key Points
- Interested in Paladin Energy Ltd? Here are five stocks we like better.
- Langer Heinrich finished its ramp-up and is now in stable operations, with fiscal 2026 production of 4.82
Die Society for Medical Decision Making ehrt UMIT TIROL- und Harvard-Professor Uwe Siebert mit dem „Career Achievement Award 2026“
OSLO, Norwegen, July 21, 2026 (GLOBE NEWSWIRE) -- Die Society for Medical Decision Making (SMDM) verlieh ihre höchste Auszeichnung für das Lebenswerk, den 2026 Career Achievement Award, an
Die Society for Medical Decision Making ehrt UMIT TIROL- und Harvard-Professor Uwe Siebert mit dem „Career Achievement Award 2026“
OSLO, Norwegen, July 21, 2026 (GLOBE NEWSWIRE) -- Die Society for Medical Decision Making (SMDM) verlieh ihre höchste Auszeichnung für das Lebenswerk, den 2026 Career Achievement Award, an
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Dräger erhält weitere Zollrückerstattungen und hebt Prognose an
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Dräger erhält weitere Zollrückerstattungen und hebt Prognose an